<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010397</url>
  </required_header>
  <id_info>
    <org_study_id>IPM-2016</org_study_id>
    <nct_id>NCT03010397</nct_id>
  </id_info>
  <brief_title>Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>PROGRESS - Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progression of Diabetic Retinopathy. Identification of Signs and Surrogate outcomes
      (PROGRESS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The global aim of this study is to improve the current knowledge of diabetic retinopathy (DR)
      progression. We aim to characterize both functionally and morphologically initial DR stages
      and to identify patients at risk of progression to centre involving macular oedema (CME)
      and/or proliferative diabetic retinopathy (PDR). We want to identify imaging patterns and
      characteristics that might be used as prognostic biomarkers for DR progression.

      For this, ischemia and blood-retinal barrier alteration will be assessed using non-invasive
      retinal imaging methodologies. SD-OCT with layer-by-layer segmentation will be performed.
      Furthermore, a state-of-the-art methodology with OCT-Angiography will be used for
      identification of areas of capillary drop-out and leakage areas will be identified on SD-OCT
      without the need of a dye injection. In a subgroup of patients we will study
      neurodegeneration patterns using multifocal ERG examination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Phenotypic classification of DR in a 5-year period</measure>
    <time_frame>5 years</time_frame>
    <description>Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DR severity level</measure>
    <time_frame>5 years</time_frame>
    <description>ETDRS grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Retinal thickness (RT) in central subfield, inner and outer rings, assessed by SD-OCT and using layer-by-layer segmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ellipsoid zone analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Degree of integrity of the ellipsoid zone, assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choroidal thickness analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Choroidal thickness assessed by Enhanced Depth Imaging (EDI) SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SD- OCT- Angiography analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Vessel analysis, assessed by SD-OCT OCT-Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT-Leakage analysis</measure>
    <time_frame>5 years</time_frame>
    <description>LOR (low optical reflectivity) ratio in central subfield, inner and outer ring for assessment of BRB breakdown, assessed by OCT-Leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness quantification</measure>
    <time_frame>5 years</time_frame>
    <description>Retinal nerve fiber layer thickness (RNFL) and ganglion cells layer (GCL) + inner plexiform layer thickness (IPL) thickness, assessed by layer-by-layer SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mfERG assessement</measure>
    <time_frame>5 years</time_frame>
    <description>P1 implicit time and P1 amplitude by ring</description>
  </secondary_outcome>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients followed under the normal clinical practice at AIBILI Clinical Trial Centre.

        - Type 2 diabetes mellitus according to 1985 WHO criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus according to 1985 WHO criteria

          -  Aged between 35 years and 80 at baseline in the retrospective period

          -  NPDR level &lt; 20 (MA absent) or Mild NPDR (levels 20 to 35, based on ETDRS criteria- 7
             fields CFP) at baseline

          -  BCVA ≥ 75 letters (≥ 20/32) at baseline (ETDRS charts)

          -  Informed Consent

        Exclusion Criteria:

          -  Inadequate ocular media and/ or pupil dilatation that interfere with fundus
             examinations

          -  HbA1C &gt; 10 % at the Screening or previous 6 months in the previous prospective study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inês P Marques, MD</last_name>
    <phone>+351 239 480 125</phone>
    <email>ipmarques@aibili.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liliana C Carvalho</last_name>
    <phone>+351239480112</phone>
    <email>lcarvalho@aibili.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aibili-Cec</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inês P Marques</last_name>
      <phone>+351 239 480 125</phone>
      <email>ipmarques@aibili.pt</email>
    </contact>
    <contact_backup>
      <last_name>Liliana C Carvalho</last_name>
      <phone>+351239480112</phone>
      <email>lcarvalho@aibili.pt</email>
    </contact_backup>
    <investigator>
      <last_name>Inês P Marques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>João P Figueira, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Lobo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria L Ribeiro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria L Cachulo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel S Pires, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

